Why the IDE892 trial update matters for IDEAYA Biosciences stock

IDEAYA Biosciences (IDYA) has moved IDE892 into Part 2 monotherapy expansion in its Phase 1/2 trial for MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma.

The IDE892 trial update lands at a time when IDEAYA Biosciences’ share price has shown firm momentum, with a 26.62% 90-day share price return and a 46.96% 1-year total shareholder return from a recent close of $36.77. This hints that investors are reassessing both growth potential and risk around its precision oncology pipeline.

If you are looking beyond IDEAYA Biosciences for other precision oncology opportunities, this is a good moment to see what else is emerging through the 41 healthcare AI stocks

After a strong 1-year move and a recent catalyst around IDE892, the question for IDEAYA Biosciences is whether the market has already priced in most of that pipeline optimism or if meaningful upside still lies ahead.

Preferred Price-to-Sales of 15.5x for IDEAYA Biosciences: Is it justified?

On a P/S basis, IDEAYA Biosciences trades at 15.5x revenue, which sits below the peer average of 29.3x but above the US biotechs industry average of 10.8x.

The P/S ratio compares the company’s market value to its revenue, so for IDEAYA Biosciences it effectively shows how much investors are currently paying for each dollar of sales. For a business that is still loss making, this kind of multiple is often used as a rough shorthand for how optimistic the market is about future revenue potential and the commercial impact of its pipeline.

Here, the data sends a mixed message. On one hand, the P/S of 15.5x is described as good value relative to a peer group average of 29.3x, which suggests the stock is priced at a discount to similar companies. On the other hand, the same 15.5x is described as expensive compared with the US biotechs industry average of 10.8x and an estimated fair P/S ratio of 3.7x, a level the market could eventually move closer to if sentiment cools.

Against a broad industry benchmark, IDEAYA Biosciences is valued more richly on revenue, and relative to an estimated fair ratio it looks materially stretched, even though it sits cheaper than some closer peers.

Result: Price-to-Sales of 15.5x (OVERVALUED)

However, IDEAYA Biosciences still faces key risks, including ongoing net losses of $140.059 million and the uncertainty that surrounds clinical trial outcomes across its broad pipeline.

Another view on IDEAYA Biosciences: DCF versus P/S

While the 15.5x P/S ratio presents IDEAYA Biosciences as expensive relative to the wider US biotechs industry and its fair ratio, the SWS DCF model offers a different perspective and suggests the stock is trading below an estimated future cash flow value of $180.75. Which lens should carry more weight for you as an investor?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around IDEAYA Biosciences clearly mixed, this is a good time to review the underlying numbers yourself and decide how comfortable you are with the balance of risks and rewards. To weigh both sides in one place, start by checking the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond IDEAYA Biosciences?

If IDEAYA Biosciences has you thinking more broadly about opportunities, do not stop here, use the tools available and keep your watchlist working harder for you.

• Target potential underpriced opportunities by scanning companies with strong fundamentals and reasonable valuations through the 51 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that show robust finances and conservative leverage profiles using the 84 resilient stocks with low risk scores.
• Spot potential future leaders early by filtering for quality businesses that the market may be overlooking via the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.